The Indux™ Cortical Strip is a robust single piece construct with a unique cross- hatch pattern that Biomet Spine & Bone Healing Technologies launches. of Biomet, Inc. or one of its subsidiaries unless otherwise indicated. Rx Only. Indux™ Cancellous Sponge and Indux™ Cancellous Strip. The Indux™ Cancellous. Biomet Spine introduced Cellentra VCBM (Viable Cell Bone Matrix), the Stimulation products which includes the Indux™ Cortical Strip and.
|Published (Last):||9 July 2005|
|PDF File Size:||4.3 Mb|
|ePub File Size:||5.93 Mb|
|Price:||Free* [*Free Regsitration Required]|
With more surface area in direct contact with the osteotomy wall, this implant is designed for greater bone-to-implant contact for primary stability, an important clinical consideration when pursuing more challenging surgical protocols such as immediate loading or immediate extraction and placement cases. We believe that patents and other intellectual property will continue to be of importance in the musculoskeletal industry.
The musculoskeletal products industry is highly litigious with respect to the enforcement of patents and other intellectual property rights. This practice is reflected in our Biomer of Business Conduct and Ethics, various other compliance policies and through the responsibility of the Audit Committee of the Board of Directors to review our systems of internal control, our process for monitoring compliance with laws and regulations and our process for monitoring compliance with our Code of Business Conduct and Ethics.
In the United States, healthcare providers that purchase our products e. In addition, copies of these reports will be made available free of charge, upon written request to our Investor Relations Department at 56 East Bell Drive, Warsaw, IN We will not be able to control many of these factors, such as economic conditions in the markets where we operate and pressure from competitors. We inrux not be able to consummate those dispositions or to obtain the proceeds that we could realize from them and these proceeds may not be adequate to meet any debt service obligations then due.
In addition, the terms inddux certain of the outstanding indebtedness of subsidiaries of LVB substantially restricts our ability to pay dividends.
If someone claims that our products infringed their intellectual property rights, any resulting litigation could be costly and time consuming and would divert the attention of management and key personnel from other business issues.
We are producing responsive documents and are fully cooperating in the investigation. We conduct a significant amount of our sales activity outside of the United States, which subjects us to additional business risks and may adversely affect our results due to increased costs.
In recent years the Chinese economy has undergone various developments, including beginning the transition from a more heavily government influenced-planned economy to a more market- oriented economy. Any of these adverse consequences could have a material adverse effect on imdux business, financial condition, results of operations and cash flows. Our team is led by Jeffrey R. Precision Machined Allograft Services.
By holding and stabilizing alignment of the reduced fracture, internal fixation products are intended to aid in the healing process and may be removed when healing is complete.
In many countries, hospitals and clinics are government-owned and healthcare professionals employed by such hospitals and clinics, with whom we regularly interact, may meet the definition of a foreign official for purposes of the FCPA. As a result of our settlement with the DOJ and SEC related to the FCPA investigation described above, we have been and may continue to be subject to further governmental investigations by foreign governments or other claims by third parties arising from the conduct subject to the investigation.
In our industry, inventory is routinely placed at hospitals to provide the healthcare provider with the appropriate product when needed. We intend to continue ineux increase the geographic presence of each of our business categories.
Further, it is not possible to assess the impact of all risk factors on our business or the extent to which any single factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements.
We may be subject to intellectual property litigation and infringement claims, which could cause us to incur significant expenses or prevent us from selling our products. We believe this service continues to enhance our reconstructive sales by strengthening our business bimet with orthopedic surgeons and augmenting our reputation as a responsive company committed to excellent product design. Experienced and Dedicated Management Team. A company that has passed ISO audits and obtained ISO certification applicable to its activity sector is internationally recognized as having quality manufacturing processes.
We may also need to contribute additional capital to improve the capital ratios of certain of our subsidiaries, which could also affect the ability of these subsidiaries to pay dividends.
During the first and second quarters of fiscal yearsubsequent closings in various foreign countries occurred on a staggered basis, with the final closing occurring on December 7, We test our goodwill and indefinite lived intangible asset balances as of March 31 of each fiscal year bjomet impairment. Office, manufacturing and warehouse facilities of Biomet Deutschland GmbH.
Moreover, research and development efforts may require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material or other innovation. Finally, the innovative trial biomte guide provides for proper screw and plate placement.
If a business interruption claim or series of claims is in excess of our insurance coverage limits, or is not otherwise covered in whole or in part by our insurance.
Equity compensation plans not approved by security holders.
Our Puerto Rican operations principally involve the assembly of purchased components into finished products using a skilled labor force. Asset-based revolving credit facility. However, a significant portion of our products are produced at and shipped from our facility in Warsaw, Indiana.
With a few exceptions, none of our raw material requirements are limited to any material extent by critical supply or single origins.
We particularly plan to focus on deepening our position in under-penetrated regions where we believe there are attractive opportunities for growth, including Asia and Latin America, by deploying more resources to capture market opportunities, as well as by leveraging our established worldwide inux facilities and sales force.
We maintain trade accounts receivable balances based on credit terms that are generally consistent with industry and local market practices. Trauma Internal Fixation Devices. As planning and guide fabrication are based upon computed tomography scans, this may result in biomrt accurate implant placement when combined with the depth and rotational control offered by our instrumentation. Principal Accounting Fees and Services. We do not undertake any obligation to publicly release any revisions to these bjomet statements to reflect events or circumstances after the date of this annual report or to reflect the occurrence of unanticipated events.
bbiomet We currently have more than 2, patents and in excess of pending patent applications. This Form K is a combined annual report being filed separately by two registrants: Zimmer Biomet Spine bioet an innovative stimulation technology that stands the test of time. Given these inherent risks and uncertainties, investors are cautioned not to place undue reliance on forward-looking statements as a prediction of actual results.
Noteholders will not have a claim as a creditor against any subsidiary that is no longer a guarantor of the notes, and the indebtedness and other liabilities, including trade payables, whether secured or unsecured, of those subsidiaries will effectively be senior to claims of noteholders. We can make no assurances as indyx the time or resources that will be needed to devote to this litigation or its final outcome.